0001822479-26-000031
SEC filingQ1 delivered 10.0% revenue growth to $280.0M and swung to $26.6M net income from a prior-year loss, driven by pricing benefits, favorable FX changes, and volume/mix gains, despite higher costs and elevated capex for long-term capacity.
Sotera Health Company reported strong Q1 FY2026 results, with revenue growing 10.0% to $280.0 million from $254.5 million in the prior year. This top-line momentum stemmed primarily from benefits in pricing, favorable changes in foreign currency exchange rates, and increases in volume/mix, partially offset by higher costs as noted in management discussion. These drivers underscore the company's ability to leverage its essential sterilization and medical device services amid healthcare demand.
Gross profit advanced 8.6% to $147.1 million, achieving a 52.5% margin on higher revenues. The margin reflected resilience despite cost pressures, including elevated employee compensation, increased depreciation from recently placed capital assets, and higher direct material costs mainly driven by greater volumes. These dynamics highlight operational leverage from scale, even as investments in workforce and infrastructure supported growth.
Net income marked a significant turnaround to $26.6 million profit from a $13.3 million loss in Q1 FY2025, delivering diluted EPS of $0.09 versus -$0.05. This 300.5% improvement in net income and 280.0% EPS growth demonstrate enhanced profitability from revenue gains outpacing cost inflation, positioning the company for sustained earnings momentum.
For the Nordion segment, income and margin expansion arose from higher volume and mix due to favorable Co-60 harvest schedule timing, complemented by pricing and FX tailwinds, offset by inflation. Overall, these results reflect disciplined execution on pricing power and volume opportunities in a mission-critical industry, with capex signaling confidence in durable growth prospects despite near-term cash conversion pressures.